Long term follow-up of Behcet's syndrome patients treated with cyclophosphamide

Gurcan M., Esatoglu S. N., HAMURYUDAN V., Saygin D., UĞURLU S., SEYAHİ E., ...More

RHEUMATOLOGY, vol.59, no.9, pp.2264-2271, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 59 Issue: 9
  • Publication Date: 2020
  • Doi Number: 10.1093/rheumatology/kez598
  • Journal Name: RHEUMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Page Numbers: pp.2264-2271
  • Istanbul University Affiliated: Yes


Objectives. CYC remains an important treatment option for Behcet's syndrome (BS) patients with life-threatening manifestations. However, adverse events may occur with CYC and this has led to increased use of biologic agents in other vasculitides. We investigated short and long term adverse events associated with CYC use in BS patients.